See the full press release on our Home page. This is an interesting and potentially important development especially for newly diagnosed with existing cardiovascular comorbidities and possible adverse effects of other TKI therapies.
It is also a way for newly diagnosed patients in general to access bosutinib as first line treatment.
Sandy
London, UK, January 09, 2014 --
The Avillion Group (Avillion), a co-developer of late-stage clinical assets, announced today that it has entered into an exclusive collaborative development agreement with Pfizer Inc. to conduct a global Phase 3 clinical trial of Pfizer’s BOSULIF® (bosutinib).